Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021092427 - REPLICATION-ENHANCED ONCOLYTIC ADENOVIRUSES

Publication Number WO/2021/092427
Publication Date 14.05.2021
International Application No. PCT/US2020/059466
International Filing Date 06.11.2020
IPC
A61K 35/761 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
C12N 7/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
CPC
A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 2710/10021
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/10032
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/10043
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10041Use of virus, viral particle or viral elements as a vector
10043viral genome or elements thereof as genetic vector
C12N 2710/10071
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10071Demonstrated in vivo effect
Applicants
  • MEMGEN, INC. [US]/[US]
  • H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. [US]/[US]
Inventors
  • CANTWELL, Mark, J.
  • BEG, Amer, A.
Agents
  • PESCHEL, Leisa, Talbert
  • ROURK, Christopher
  • LALLY, Joseph
  • CRAVEY, Christopher
  • DEWAN, Raman
Priority Data
62/931,28206.11.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) REPLICATION-ENHANCED ONCOLYTIC ADENOVIRUSES
(FR) ADÉNOVIRUS ONCOLYTIQUES À RÉPLICATION AMÉLIORÉE
Abstract
(EN)
Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.
(FR)
L'invention concerne des adénovirus oncolytiques à réplication améliorée. Ces adénovirus oncolytiques ont une réplication spécifique de tumeurs capable d'une oncolyse tumorale améliorée et d'une expression améliorée de transgènes thérapeutiques. L'invention concerne également des procédés comprenant l'administration d'un adénovirus oncolytique à réplication améliorée pour des patients souffrant d'un cancer.
Latest bibliographic data on file with the International Bureau